An erectile dysfunction drug from South Korea could become the first pill approved in the United States to slow Alzheimer’s disease.
Researchers announced this week that a lower-dose version of the drug — sold as Mvix in South Korea for erectile dysfunction — helped slow mental decline in a yearlong trial of more than 1,500 people with early-stage Alzheimer’s, The Washington Post reported. But the experimental treatment, called AR1001, appeared to work only in those who were not taking other medications for dementia.
Among the roughly 40% of participants who weren’t taking other dementia drugs, the pill slowed decline by about 31% compared with the placebo group. The rest of the participants, those who were on other dementia medications, exhibited little to no benefit. Across the full trial population, the benefit was not statistically significant. Researchers measured decline through assessments that included interviews with the patients and their caregivers about memory, judgment, and their daily lives.
AriBio, the South Korean company repurposing the drug, said it plans to discuss with the Food and Drug Administration whether the trial results are sufficient or whether another trial is needed.
If the low-dose version of Mvix were to get approved, it would be the first pill authorized in the country to slow Alzheimer’s, according to Sharon Sha, a neurologist who directs the Stanford Center for Memory Disorders and led the trial.
Sha presented the group’s findings at the Clinical Trials on Alzheimer’s Disease conference on Monday.
“To have a disease-modifying drug with relatively minimal side effects that is oral would be huge,” she said. “It’s very exciting and promising.”
Reported side effects included diarrhea, dizziness, falls and fainting.
AriBio has been testing the Viagra-like drug since late 2022 at a daily dose of 30 milligrams — less than a third of the 100-milligram dose used for erectile dysfunction.
Richard Oakley, an associate director for research and innovation at Alzheimer’s Society in the United Kingdom, said the results could change the future of Alzheimer’s treatment.
“These topline results are an exciting sign that we could have a totally new treatment for early Alzheimer’s disease that tackles its causes, not just its symptoms,” he said. “[The drug] takes a novel approach, relaxing blood vessels to increase blood flow to the brain. And unlike other disease-modifying treatments that have shown benefits in late-stage trials, it is taken as a once-a-day tablet, which could make treatment simpler.”

.png)
.png)

